Actinic keratosis: A clinical and epidemiological revision;Queratoses actínicas: Revisão clínica e epidemiológica

Anais Brasileiros de Dermatologia

Volumn 87, Issue 3, 2012, Pages 425-434

  Schmitt, Juliano Vilaverde ^a   Miot, Héio Amante ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Actinic; Apoptosis; Carcinoma; Epidemiology; Keratosis; Squamous cell; Ultraviolet rays

Indexed keywords

BETA CATENIN; CELECOXIB; COLCHICINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PROTEIN P63; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SORAFENIB; SUNSCREEN; TRICHLOROACETIC ACID; WNT PROTEIN;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONSULTATION; CRYOTHERAPY; DISEASE ASSOCIATION; DNA REPAIR; EARLY DIAGNOSIS; ELECTROCOAGULATION; EPIDEMIOLOGICAL DATA; EXCISION; FOLLOW UP; HEALTH EDUCATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; KERATINOCYTE; LOW LEVEL LASER THERAPY; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PHOTODYNAMIC THERAPY; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SELF EXAMINATION; SKIN ABRASION; SKIN CANCER; SKIN CARE; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

HUMANS; KERATOSIS, ACTINIC; RISK FACTORS; ULTRAVIOLET RAYS;

EID: 84863093577     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000300012     Document Type: Review

References (127)

1. Goldberg LH, Mamelak AJ. Review of actinic kurtosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol. 2010;9:1125-1132.
2. Babilas P, Landthaler M, Szeimies RM. [Actinic keratoses]. Hautarzt. 2003;54:551-560.
3. Castro IA, Schütz LC, Capp E, Bakos L. Ceratoses actínicas. Rev HCPA. 2006;26:66-72.
4. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189-196.
5. Lanssens S, Ongenae K. Dermatologic lesions and risk for cancer. Acta Clin Belg. 2011;66:177-185.
6. Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996;15:134-138.
7. Chia A, Moreno G, Lim A, Shumack S. Actinic keratoses. Aust Fam Physician. 2007;36:539-543.
8. Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Arch Intern Med. 1998;158:726-730.
9. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003;149 Suppl 66:31-33.
10. Sociedade Brasileira de Dermatologia SBD. Perfil nosológico das consultas dermatológicas no Brasil. An Bras Dermatol. 2006;81:549-558.
11. Bernard P, Dupuy A, Sasco A, Brun P, Duru G, Nicoloyannis N, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a crosssectional survey. Dermatology. 2008;216:194-199.
12. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455-464.
13. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46:895-904.
14. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157 Suppl 2:21-24.
15. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and patho biology of actinic (solar) keratosis- an update. Br J Dermatol 2007;157 Suppl 2:18-20.
16. Ishioka P, Marques SA, Hirai AT, Marques ME, Hirata SH, Yamada S. Prevalence of precancerous skin lesions and non-melanoma skin cancer in Japanese-Brazilians in Bauru, São Paulo State, Brazil. Cad Saude Publica. 2009;25:965-971.
17. Kim HS, Cho EA, Bae JM, Yu DS, Oh ST, Kang H, et al. Recent trend in the incidence of premalignant and malignant skin lesions in Korea between 1991 and 2006. J Korean Med Sci. 2010;25:924-929.
18. Kennedy C, Bajdik CD, Willemze R, De Gruijl FR, Bouwes Bavinck JN; Leiden Skin Cancer Study. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol. 2003;120:1087-1093.
19. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4-7.
20. Garg S, Carroll RP, Walker RG, Ramsay HM, Harden PN. Skin cancer surveillance in renal transplant recipients: re-evaluation of U.K. practice and comparison with Australian experience. Br J Dermatol. 2009;160:177-179.
21. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients-- where do we stand today? Am J Transplant. 2008;8:2192-2198.
22. Dornelas MT, Rodrigues MF, Machado DC, Gollner A, Ferreira AP. Expressão de marcadores de proliferação celular e apoptose no carcinoma espinocelular de pele e ceratose actínica. An Bras Dermatol. 2009;84:469-475.
23. Chinem VP, Miot HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86:292-305.
24. Keller B, Braathen LR, Marti HP, Hunger RE. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly. 2010;140:w13036.
25. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000;42:18-22.
26. Berking C. [The role of ultraviolet irradiation in malignant melanoma]. Hautarzt. 2005;56:687-696.
27. Arrington JH, Lockman DS. Thermal keratoses and squamous cell carcino ma in situ associated with erythema ab igne. Arch Dermatol. 1979;115:1226-1228.
28. Eskelinen A, Halme K, Lassus A, Idänpään-Heikkilä J. Risk of cutaneous carcinoma in psoriatic patients treated with PUVA. Photodermatol. 1985;2:10-14.
29. Balogh TS, Velasco MVR, Pedriali CA, Kaneko TM, Baby AR. Proteção à radiação ultravioleta: recursos disponíveis na atualidade em fotoproteção. An Bras Dermatol. 2011;86:732-742.
30. Lever LR, Farr PM. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol. 1994;131:215-219.
31. Nindl I, Gottschling M, Krawtchenko N, Lehmann MD, Röwert-Huber J, Eberle J, et al. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol. 2007;156 Suppl 3:34-39.
32. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL. [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006;37:757-760.
33. Muller-Decker K, Charyalertsak S, Albert C, Reinerth G, Marks F, Furstenberger G. Cyclooxygenase-2: a molecular target for chemoprevention of epithelial tumors of skin and colon. Adv Exp Med Biol. 2002;507:445-448.
34. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A. 2002;99:12483-12488.
35. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 2002;62:3395-3401.
36. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol. 2002;146:810-815.
37. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156 Suppl 3:25-33.
38. Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 2006;126:1143-1151.
39. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol. 2004;151:837-845.
40. Wu Y, Liu H, Li J. Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors. J Huazhong Univ Sci Technolog Med Sci. 2007;27:206-208.
41. Ouyang W, Zhang D, Ma Q, Li J, Huang C. Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect. 2007;115:513-518.
42. Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D. Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol. 2004;26:177-181.
43. Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J Cutan Pathol. 2004;31:544-549.
44. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:698-704.
45. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002;198:417-427.
46. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol. 1999;113:1099-1105.
47. Salama ME, Mahmood MN, Qureshi HS, Ma C, Zarbo RJ, Ormsby AH. P16INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol. 2003;149:1006-1012.
48. Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, et al. Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol. 2010;19:151-153.
49. Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol. 2009;161:1112-1118.
50. Takahara M, Chen S, Kido M, Takeuchi S, Uchi H, Tu Y, et al. Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes. J Cutan Pathol. 2009;36:668-674.
51. Jang TJ. Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei Med J. 2008;49:942-948.
52. Forslund O, Lindelöf B, Hradil E, Nordin P, Stenquist B, Kirnbauer R, et al. High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in Stripped biopsies from the same tumors. J Invest Dermatol. 2004;123:388-394.
53. McBride P, Neale R, Pandeya N, Green A. Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study. Arch Dermatol. 2007;143:862-868
54. Plasmeijer EI, Neale RE, de Koning MN, Quint WG, McBride P, Feltkamp MC, et al. Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res. 2009;69:8926-831.
55. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005;125:93-97.
56. Zaravinos A, Kanellou P, Spandidos DA. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol. 2010;162:325-331.
57. Guarneri F, Asmundo A, Sapienza D, Gazzola A, Cannavo SP. Polymorphism of glutathione S-transferases M1 and T1: susceptibility to solar keratoses in an Italian population. Clin Exp Dermatol. 2010;35:771-775.
58. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer. 2005;5:564-573.
59. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147-1151.
60. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol. 2000;115:273-277.
61. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-2530.
62. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37:677-681.
63. Marks VJ. Actinic keratosis. A premalignant skin lesion. Otolaryngol Clin North Am. 1993;26:23-35.
64. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146:288-293.
65. Schwarze HP, Loche F, Gorguet MC, Kuchta J, Bazex J. Invasive cutaneous squamous cell carcinoma associated with actinic keratosis: a case with orbital invasion and meningeal infiltration. Dermatol Surg. 1999;25:587-589.
66. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007;33:1099-1101.
67. Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang SH, Gill I, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg. 2005;31:43-47.
68. Hensen P, Müller ML, Haschemi R, Ständer H, Luger TA, Sunderkötter C, et al. Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol. 2009;19:345-354.
69. Savoia P, Stroppiana E, Cavaliere G, Osella-Abate S, Mezza E, Segoloni GP, et al. Skin cancers and other cutaneous diseases in renal transplant recipients: a single Italian center observational study. Eur J Dermatol. 2011;21:242-247.
70. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-23.
71. Schmid-Wendtner MH, Wendtner CM. Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia. Dermatology. 2009;219:341-43.
72. Hancox JG, Sheridan SC, Feldman SR, Fleischer AB Jr. Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. Int J Dermatol. 2004;43:6-11.
73. Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. 1999;40:114-116.
74. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78-84.
75. Vitasa BC, Taylor HR, Strickland PT, Rosenthal FS, West S, Abbey H, et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer. 1990;65:2811-2817.
76. Araki K, Nagano T, Ueda M, Washio F, Watanabe S, Yamaguchi N, et al. Incidence of skin cancers and precancerous lesions in Japanese--risk factors and prevention. J Epidemiol. 1999;9:S14-S21.
77. Melkonian S, Argos M, Pierce BL, Chen Y, Islam T, Ahmed A, et al. A prospective study of the synergistic effects of arsenic exposure and smoking, sun exposure, fertilizer use, and pesticide use on risk of premalignant skin lesions in Bangladeshi men. Am J Epidemiol. 2011;173:183-191.
78. Akimoto S, Suzuki Y, Ishikawa O. Multiple actinic keratoses and squamous cell carcinomas on the sun-exposed areas of widespread vitiligo. Br J Dermatol. 2000;142:824-825.
79. Hughes MC, Williams GM, Fourtanier A, Green AC. Food intake, dietary patterns, and actinic keratoses of the skin: a longitudinal study. Am J Clin Nutr. 2009;89:1246-1255.
80. Black HS, Herd JA, Goldberg LH, Wolf JE Jr, Thornby JI, Rosen T, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994;330:1272-1275.
81. Abel EL, Hendrix SO, McNeeley SG, Johnson KC, Rosenberg CA, Mossavar- Rahmani Y, et al. Daily coffee consumption and prevalence of nonmelanoma skin cancer in Caucasian women. Eur J Cancer Prev. 2007;16:446-452.
82. Grau de Castro JJ. [COX-2 inhibitors in cancer prevention]. Rev Clin Esp. 2005;205:446-456.
83. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20:482-488.
84. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol. 2010;24:258-263.
85. Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008;19:159-163.
86. Nelson C, Rigel D. Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation. J Clin Aesthet Dermatol. 2009;2:20-25.
87. Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol. 2006;72:346-349.
88. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005;53:966-972.
89. Tang X, Kim AL, Kopelovich L, Bickers DR, Athar M. Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice. Photochem Photobiol. 2008;84:522-527.
90. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep. 2008;19:547-553.
91. Yu RC, Pryce DW, Macfarlane AW, Stewart TW. A histopathological study of 643 cutaneous horns. Br J Dermatol. 1991;124:449-452.
92. Dergham AP, Muraro CC, Ramos EA, Mesquita LAF, Collaço LM. Distribuição dos diagnósticos de lesões pré-neoplásicas e neoplásicas de pele no Hospital Universitário Evangélico de Curitiba. An Bras Dermatol. 2004;79:555-559.
93. Venna SS, Lee D, Stadecker MJ, Rogers GS. Clinical recognition of actinic keratoses in a high-risk population: how good are we? Arch Dermatol. 2005;141:507-509.
94. Epstein E. Quantifying actinic keratosis: assessing the evidence. Am J Clin Dermatol. 2004;5:141-144.
95. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006;32:1261-165.
96. Ulrich M, Forschner T, Röwert-Huber J, González S, Stockfleth E, Sterry W, et al. Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy. Br J Dermatol. 2007;156 Suppl 3:47-52.
97. Mogensen M, Jemec GB. Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg. 2007;33:1158-1174.
98. Butani AK, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma. Clin Plast Surg. 2005;32:223-235.
99. Quaedvlieg PJ, Ostertag JU, Krekels GA, Neumann HA. Delayed wound healing after three different treatments for widespread actinic keratosis on the atrophic bald scalp. Dermatol Surg. 2003;29:1052-1056.
100. Wood NH, Khammissa R, Meyerov R, Lemmer J, Feller L. Actinic cheilitis: a case report and a review of the literature. Eur J Dent. 2011;5:101-106.
101. Rossoe EWT, Tebcherani AJ, Sittart JA, Pires MC. Queilite actínica: avaliação comparative estética e funcional entre as vermelhectomias clássica e em W-plastia. An Bras Dermatol. 2011;86:65-73.
102. Lee K, Weinstock M. Prospective quality of life impact of actinic keratoses: observations from the veterans affairs topical tretinoin chemoprevention trial. Acta Derm Venereol. 2011;91:101-102.
103. Cockerell CJ. Pathology and pathobiology of the actinic (solar) keratosis. Br J Dermatol. 2003;149 Suppl 66:34-36.
104. Krouse RS, Alberts DS, Prasad AR, Yozwiak M, Bartels HG, Liu Y, et al. Progression of skin lesions from normal skin to squamous cell carcinoma. Anal Quant Cytol Histol. 2009;31:17-25.
105. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157 Suppl 2:47-51.
106. Bartels PH, Krouse RS, Prasad AR, Yozwiak M, Liu Y, Bartels HG, et al. Actinic damage in histopathologically normal skin. Anal Quant Cytol Histol. 2008;30:316-322.
107. James C, Crawford RI, Martinka M, Marks R. Actinic keratosis. In: James C, Crawford RI, Martinka M, Marks R, editors. Pathology & Genetics, Skin tumors. Lyon: IARC Press; 2006. p.30-33.
108. Yantsos VA, Conrad N, Zabawski E, Cockerell CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999;18:3-14.
109. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinickeratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156 Suppl 3:8-12.
110. Lober BA, Lober CW, Accola J. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol. 2000;43:881-882.
111. Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol. 2003;48:637-638.
112. Ko CJ. Actinic keratosis: facts and controversies. Clin Dermatol. 2010;28:249-53.
113. Petit A. [Actinic keratoses are still actinic keratoses]. Ann Dermatol Venereol. 2008;135:93-96.
114. Deltondo JA, Helm KF. Actinic keratosis: precancer, squamous cell carcinoma, or marker of field cancerization? G Ital Dermatol Venereol. 2009;144:441-444.
115. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-230.
116. Rossi R, Calzavara-Pinton PG, Giannetti A, Peserico A, Santucci M, Vena GA, et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol. 2009;144:713-723.
117. Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. Cutis. 2011;88:Suppl 1-8.
118. Borgonjen RJ, van Everdingen JJ, Bik CM, Tuut MK, Spuls PI, van de Kerkhof PC. Prospective comparison of three guideline development methods for treatment of actinic keratosis. BMJ Qual Saf. 2011;20:832-841.
119. Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat. 2009;20:266-275.
120. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008;7:23-25.
121. Deonizio JMD, Mulinari-Brenner FA. Cryopeeling for treatment of photodamage and actinic keratosis: liquid nitrogen versus portable system. An Bras Dermatol. 2011;86:440-444.
122. Ritter CG, Kuhl ICP, Lenhardt C, Weissbluth ML, Bakos RM. Terapêutica fotodinâmica com ácido delta-aminolevulínico e luz de diodos em ceratoses actínicas. An Bras Dermatol. 2010;85:639-645.
123. Poziomczyk CS, Köche B, Dornelles MA, Dornelles SIT. Avaliação da dor em criocirurgia de ceratoses actínicas. An Bras Dermatol. 2011;86:645-650.
124. Fenske NA, Spencer J, Adam F. Actinic keratoses: past, present and future. J Drugs Dermatol. 2010;9:(5 Suppl ODAC Conf Pt 1):s45-s49.
125. Strickland PT, Vitasa BC, West SK, Rosenthal FS, Emmett EA, Taylor HR. Quantitative carcinogenesis in man: solar ultraviolet B dose dependence of skin cancer in Maryland watermen. J Natl Cancer Inst. 1989;81:1910-1913.
126. Sociedade Brasileira de Dermatologia. Análise de dados das campanhas de prevenção ao câncer da pele promovidas pela Sociedade Brasileira de Dermatologia de 1999 a 2005. An Bras Dermatol. 2006;81:533-539.
127. Feldman SR, Fleischer AB, Jr. Skin examinations and skin cancer prevention counseling by US physicians: a long way to go. J Am Acad Dermatol. 2000;43:234-237.